DIAGNOS Announces Contract with Novartis Pharma AG BROSSARD, QUEBEC -- (Marketwire) -- 01/15/13 -- Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK) is proud to announce today the signing of an agreement with Novartis Pharma AG, for the continuation and expansion of joint deployment and usage of CARA in the United Arab Emirates. Novartis' team in the United Arab Emirates view our CARA screening platform as an excellent tool within the context of their activities. With our assistance, they hope to slow or reverse vision impairment caused by a high prevalence of diabetes within a large patient population. "Novartis' leadership and support will make these initiatives feasible and will undoubtedly greatly benefit the local population. We are very excited with this important relationship. Under the terms of this first agreement, DIAGNOS will continue to conduct deployments within the UAE including both stationary and mobile applications for an initial amount of $100,000, with the objective to scale-up subsequently within the UAE and the Middle East. We are presently working on putting in place relationships of a similar nature in certain areas in North America, Latin America, and Asia." said Peter Nowacki, Diagnos' Vice-President. About Novartis Pharma AG Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization) was invested in R&D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 119,000 full-time-equivalent associates (including 16,700 Alcon associates) and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com. About DIAGNOS Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologi es combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources. CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union. For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release. Contacts: Andre Larente, President and CEO DIAGNOS inc. 1-877-678-8882 or (450) 678-8882, ext.: 224 email@example.com Louis Morin Bid Capital Markets (514) 845-1101 firstname.lastname@example.org
DIAGNOS Announces Contract with Novartis Pharma AG
Press spacebar to pause and continue. Press esc to stop.